Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The ability to adapt to new task demands flexibly and to stabilise performance in the presence of distractors is termed cognitive control and is mediated by dopaminergic and cholinergic neurotransmission.

The researchers aimed to test the hypothesis that the effect of the cholinergic agonist nicotine on cognitive control depends on baseline dopamine levels.

Who Took Part

The age groups tagged for this paper are young adults, both men and women.

Thirty-eight healthy non-smokers (16 males; Mage=24.05 years) performed a cognitive control task including distractor and switch trials twice.

Subjects were split into two parallel groups.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled, parallel-group and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

Response time costs for distractor and switch trials served as measures of cognitive stability and flexibility.

What Was Measured

Topics PubMed links to this paper include Cognition, Dopamine, Nicotine, Nicotinic Agonists, Pilot Projects, Reaction Time and Tobacco Use Cessation Devices.

Author keywords: L-tyrosine, acetylcholine, attention and psychopharmacology.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of psychopharmacology (Oxford, England)), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.